Comparative Pharmacology
Head-to-head clinical analysis: PREFRIN A versus VISINE L R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREFRIN A versus VISINE L R.
PREFRIN-A vs VISINE L.R.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
Selective alpha-1 adrenergic receptor agonist; constricts conjunctival blood vessels via stimulation of alpha-1 adrenoreceptors in the ophthalmic artery, reducing redness and edema.
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
1 to 2 drops in the affected eye(s) every 8 to 12 hours, not to exceed 2 drops per eye every 8 hours. Ophthalmic solution 0.05%.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism.
Terminal elimination half-life is 2.1 ± 0.2 hours for the racemic mixture; clinical context: dosing intervals typically every 4-6 hours.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites.
Primarily renal excretion of unchanged drug and metabolites; ~90% of an oral dose is excreted in urine within 24 hours; biliary/fecal excretion accounts for <5%.
Category C
Category C
Ophthalmic Decongestant/Antihistamine Combination
Ophthalmic Decongestant